山东东方海洋科技股份有限公司 章程修订对照表 山东东方海洋科技股份有限公司（以下简称"公司"）根据《中华人民共和国 公司法（2023 年修订）》《上市公司章程指引》《上市公司监管指引第 3 号—— 上市公司现金分红》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作（2023 年 12 月修订）》《上市公司独立董事管理办法》等法律 法规及规范性文件相关规定，同时结合公司实际情况对《公司章程》进行相应修 订，具体修订情况如下： | 修订前 | 修订后 | | --- | --- | | 第六条 公司注册资本为人民币 75,635 万元。 | 第六条 公司注册资本为人民币 195,894.65 万元。 | | 第十二条 公司应积极建立健全投资者关系管理工作 | 第十二条 公司根据《中国共产党章程》的规定，设 | | 制度，通过多种形式主动加强与股东特别是社会公众 | 立共产党组织、开展党的活动；在上级党委领导下， | | 股股东的沟通和交流。公司董事会秘书具体负责公司 | 围绕企业生产经营开展工作，发挥政治核心作用，参 | | 投资者关系管理工作。 | 与企业重大问题的决策；公司建立党的工作 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2024-044 山东东方海洋科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 2、公司未发现近期公共传媒报道可能或已对公司股票交易价格产生较大影 响的未公开重大信息； 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、目前公司无控股股东、无实际控制人。经核查，公司及公司第一大股东 五矿金通股权投资基金管理有限公司不存在关于公司应披露而未披露的重大事 项或处于筹划阶段的重大事项，在公司股票异常波动期间，未出现第一大股东 买卖公司股票的情形； 5、公司不存在违反公平信息披露的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市规 1 山东东方海洋科技股份有限公司（证券代码：002086，证券简称：*ST 东洋， 以下简称"公司"）股票连续三个交易日（2024年4月29日、2024年4月30日、2024年 5月6日）收盘价格跌幅偏离值累计超过12%。根据《深圳证券交易所 ...

山东东方海洋科技股份有限公司 董事会议事规则 （2024 年 5 月修订） 第一章 总则 第一条 为规范山东东方海洋科技股份有限公司（以下简称"公司"）董事会 议事的方法和程序，确保董事会的工作效率，提高董事会工作的科学性，充分维 护全体股东的合法权益，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《深圳证券交易所上市公 司自律监管指引第 1 号—主板上市公司规范运作》、《深圳证券交易所股票上市 规则》（以下简称《股票上市规则》）、《上市公司独立董事管理办法》及《山 东东方海洋科技股份有限公司章程》（以下简称《公司章程》）及其他有关法律、 行政法规和规范性文件的规定，特制定本规则。 第二条 董事会是公司经营决策的常设机构，对股东大会负责，在法律、行 政法规、部门规章、规范性文件、《公司章程》和股东大会赋予的职权范围内行 使权力。 第三条 董事会应当自觉维护公司党委发挥把方向、管大局、促落实的领导 作用，支持党委按照规定在重大事项决策中履行决定或者把关定向职责，自觉接 受党委对其行权履职的监督。董事会决定公司重大事项时，应依照《公司章程》 的规定事先听取公 ...

因变更上述相应条款并依次对原条款序号作相应调整。 除上述修订内容和条款外，《股东大会议事规则》其他条款保持不变。《股东 大会议事规则》中其他修订系非实质性修订，如条款编号、引用条款所涉及条款 编号变化、标点的调整等，因不涉及权利义务变动，不再作一一对比。 | 修订前 | 修订后 | | --- | --- | | 第七条 独立董事有权向董事会提议召开临时股东大 | 第七条 独立董事有权向董事会提议召开临时股东 | | 会。对独立董事要求召开临时股东大会的提议,董事会 | 大会。独立董事行使该职权的，应当经全体独立董 | | 应当根据法律、行政法规和公司章程的规定,在收到提 | 事过半数同意且应当经独立董事专门会议审议通 | | 议后 日内提出同意或不同意召开临时股东大会的 10 | 过。对独立董事要求召开临时股东大会的提议，董 | | 书面反馈意见。 | 事会应当根据法律、行政法规和公司章程的规定， | | …… | 在收到提议后 日内提出同意或不同意召开临时股 10 | | | 东大会的书面反馈意见。 | | | 独立董事行使上述职权的，公司应当及时披露。上 | | | 述职权不能正常行使的，公司应当披露具 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2024-042 山东东方海洋科技股份有限公司 关于股东提请增加股东大会临时提案的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2024 年 5 月 6 日，公司第八届董事会第九次会议审议通过了《关于修订<公司 章程>的议案》《关于修订<股东大会议事规则>的议案》《关于修订<关联交易决 策制度>的议案》《关于修订<董事会议事规则>的议案》《关于股东提请增加股东 大会临时提案的议案》，故公司董事会同意将上述临时提案提交至公司 2024 年 5 月 15 日召开的 2024 年第一次临时股东大会一并审议。 山东东方海洋科技股份有限公司（以下简称"公司"）于 2024 年 5 月 4 日收到 烟台市正大城市建设发展有限公司（以下简称"正大城投"）提交的《关于提请 山东东方海洋科技股份有限公司 2024 年第一次临时股东大会增加临时提案的函》， 具体内容如下： 根据《公司法》《公司章程》《股东大会议事规则》的相关规定，正大城投 作为持有公司 3%以上股份的股东，现向公司将于 2024 年 5 月 15 日召 ...

暨股东大会补充通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 4 月 29 日召开第八届董事会第八次会议审议通过了《关于召开 2024 年第一次临时 股东大会的议案》，决定于 2024 年 5 月 15 日召开 2024 年第一次临时股东大会。 公司董事会于 2024 年 5 月 4 日收到烟台市正大城市建设发展有限公司（以 下简称"正大城投"）书面出具的《关于提请山东东方海洋科技股份有限公司 2024 年第一次临时股东大会增加临时提案的函》，提请将《关于修订<公司章程> 的议案》《关于修订<股东大会议事规则>的议案》《关于修订<关联交易决策制 度>的议案》《关于修订<董事会议事规则>的议案》四项议案作为临时提案提交 公司 2024 年第一次临时股东大会审议。 2024 年 5 月 6 日，公司第八届董事会第九次会议审议通过了《关于修订<公 司章程>的议案》《关于修订<股东大会议事规则>的议案》《关于修订<关联交 易决策制度>的议案》《关于修订<董事会议事规则>的议案》《 ...

因变更上述相应条款并依次对原条款序号作相应调整。 除上述修订内容和条款外，《关联交易决策制度》其他条款保持不变。《关联 交易决策制度》中其他修订系非实质性修订，如条款编号、引用条款所涉及条款 编号变化、标点的调整等，因不涉及权利义务变动，不再作一一对比。 山东东方海洋科技股份有限公司 董事会 山东东方海洋科技股份有限公司 《关联交易决策制度》修订对照表 山东东方海洋科技股份有限公司（以下简称"公司"）根据《中华人民共和 国公司法（2023 年修订）》《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第 7 号——交易与关联交易（2023 年修订）》等法律法 规及规范性文件相关规定，同时结合公司实际情况对《关联交易决策制度》进行 相应修订，具体修订情况如下： | 修订前 | 修订后 | | --- | --- | | 第十四条 | 第十四条 | | …… | …… | | 前款所称关联董事包括下列董事或者具有下列情形 | 前款所称关联董事包括下列董事或者具有下列情形 | | 之一的董事： | 之一的董事： | | （一） 交易对方； | （一） 交易对方； | | （二） 在交易对方任职，或在能 ...

证券代码：002086 证券简称：*ST 东洋 公告编号：2024-045 山东东方海洋科技股份有限公司 第八届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）第八届董事会第九次会议 于 2024 年 5 月 6 日以电话、传真及邮件等形式通知全体董事，会议定于 2024 年 5 月 6 日以通讯方式召开，应参加董事 9 人，实际参加审议董事 8 人（公司收到股东 增加临时提案的函件，根据要求需要尽快召开本次董事会，王帅先生因会议通知时 间较短，无法完成内部审批流程，故不出席本次会议）。会议的召集、召开符合《公 司法》和《公司章程》规定，会议由董事长（代行）黄治华先生召集并主持。 会议以通讯表决方式通过以下议案： 一、审议通过《关于修订<公司章程>的议案》。 根据《中华人民共和国公司法（2023 年修订）》《上市公司章程指引》《上市 公司监管指引第 3 号——上市公司现金分红》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》《上市公 ...

Financial Performance - The company's revenue for Q1 2024 was ¥66,643,850.46, representing a decrease of 50.85% compared to ¥135,602,385.62 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥14,389,779.83, contrasting with a profit of ¥11,069,061.27 in the previous year[5] - The net cash flow from operating activities was a negative ¥45,898,806.38, down 85.62% from a negative ¥24,726,935.83 year-on-year[5] - The net profit excluding non-recurring gains and losses was a loss of ¥16,687,636.90, a significant decline of 2,851.86% from a loss of ¥565,325.34 in the previous year[5] - The basic and diluted earnings per share were both -¥0.01, compared to ¥0.01 in the same period last year[5] - The weighted average return on equity was -0.89%, down from 0.00% in the previous year[5] - In Q1 2024, the company reported a net profit of -14,445,789.33 CNY, a significant decline compared to a net profit of 11,009,690.46 CNY in the same period last year, representing a year-over-year decrease of approximately 231.5%[16] - The total comprehensive income for Q1 2024 was -14,360,970.99 CNY, compared to 10,724,816.46 CNY in Q1 2023, reflecting a decline of approximately 233.8%[17] - The company reported a basic and diluted earnings per share of -0.01 CNY in Q1 2024, compared to 0.01 CNY in Q1 2023, indicating a shift from profitability to loss[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,390,485,757.37, a decrease of 11.71% from ¥2,707,578,833.26 at the end of the previous year[5] - Total assets decreased to CNY 2,390,485,757.37 from CNY 2,707,578,833.26, a decline of 11.7%[14] - Total liabilities decreased to CNY 778,115,399.31 from CNY 1,080,847,504.21, a reduction of 28.0%[14] - The company's equity attributable to shareholders decreased to CNY 1,603,095,013.71 from CNY 1,617,399,975.20, a decline of 0.9%[14] - The company reported a net loss of CNY 2,352,863,717.84 in retained earnings, compared to a loss of CNY 2,338,473,938.01 in the previous period[14] Cash Flow and Financing - The cash and cash equivalents at the end of Q1 2024 were CNY 982,225,165.62, a decrease of 23.9% from CNY 1,292,911,042.35 at the beginning of the period[12] - The cash flow from operating activities showed a net outflow of -45,898,806.38 CNY in Q1 2024, worsening from -24,726,935.83 CNY in Q1 2023[19] - The company experienced a significant increase in cash and cash equivalents, with a net increase of 216,771,770.42 CNY in Q1 2024, compared to a decrease of -28,993,800.47 CNY in Q1 2023[19] - The company generated cash inflows from financing activities amounting to 385,969,097.83 CNY in Q1 2024, a notable increase compared to the previous year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,492[9] - The largest shareholder, Wukuang Jintong Investment Fund Management Co., Ltd., held 357,660,463 shares, representing 18.26% of the total shares[9] Operating Costs and Expenses - The total operating revenue for Q1 2024 was CNY 66,643,850.46, a decrease of 50.8% compared to CNY 135,602,385.62 in the same period last year[15] - The total operating costs for Q1 2024 amounted to CNY 83,618,008.07, down from CNY 104,003,462.97 in the previous year[15] - The total operating expenses for Q1 2024 were 76,000,000.00 CNY, compared to 70,000,000.00 CNY in Q1 2023, reflecting an increase of approximately 8.6%[16] - Research and development expenses for Q1 2024 were 4,854,766.56 CNY, slightly down from 5,206,606.49 CNY in Q1 2023, marking a decrease of about 6.7%[16] Inventory and Receivables - Accounts receivable increased to CNY 49,440,422.40 from CNY 48,838,509.61, reflecting a slight increase of 1.2%[13] - Inventory rose to CNY 142,916,109.32, up from CNY 129,078,743.06, indicating an increase of 10.5%[13] Government Support - The company received government subsidies amounting to ¥2,278,973.38 during the reporting period[6] Product Development and Strategy - The company has not disclosed any new product developments or market expansion strategies in this report[11]

Financial Performance - The company's operating revenue for 2023 was CNY 437,233,445, a decrease of 30.52% compared to CNY 629,302,311 in 2022[22]. - The net profit attributable to shareholders for 2023 was CNY 1,749,600.27, compared to CNY 1,584,905.38 in 2022, reflecting an increase[22]. - The net profit after deducting non-recurring gains and losses was CNY 635,887,563, a decrease of 29.25% from CNY 898,841,849 in 2022[22]. - The net cash flow from operating activities was CNY 46,190,507.4, a decrease of 7.51% compared to CNY 42,962,176.4 in 2022[22]. - Basic and diluted earnings per share for 2023 were CNY 0.89, compared to a loss of CNY 2.10 in 2022[22]. - The company's total assets reached CNY 2,707,578,830, an increase of 35.22% compared to the previous year[24]. - The company's total revenue from processing services was CNY 89,550,255.11, a decrease of 25.21% compared to the previous year[64]. - The company's revenue from the mainland China market was CNY 245,419,092.16, a decrease of 41.91% compared to the previous year[64]. - The gross profit margin for the aquaculture industry was -83.86%, reflecting a significant decline of 7.15% year-on-year[65]. - The gross profit margin for the external diagnostic industry was 59.75%, down 5.96% from the previous year[65]. Business Operations - The company has not reported any changes in its main business operations since its listing[22]. - The company is focusing on the development of smart aquaculture technologies, aligning with national policies aimed at enhancing the fishing industry[36]. - The company is experiencing a shift from traditional extensive aquaculture to modern intensive and eco-friendly practices[37]. - The company is expanding its market presence both domestically and internationally, driven by increasing demand in the aquaculture sector[37]. - The company has established a comprehensive supply chain with a focus on product traceability to enhance food safety and meet consumer demand for high-quality seafood[38]. - The company has developed a research and promotion platform for breeding and seedling cultivation in collaboration with leading institutions, enhancing its technological capabilities[43]. - The company has achieved a leading position in the industry for sea cucumber and kelp breeding and farming technology[46]. - The company is actively expanding its market presence in Japan, South Korea, the United States, and the European Union[44]. - The company is committed to the dual-driven development of the marine and health industries, focusing on technological innovation and industry transformation[42]. Environmental and Compliance - The company emphasizes the risks associated with environmental pollution and natural disasters affecting its aquaculture operations[4]. - The company is committed to maintaining compliance with the Shenzhen Stock Exchange's disclosure requirements for the aquaculture industry[4]. - The company has implemented advanced environmental management practices and has not experienced any sudden environmental pollution incidents[185]. - The company strictly adheres to various environmental protection laws and standards, ensuring compliance in its operations[183]. - The company has established an ISO14001 environmental management system to enhance its environmental management capabilities and competitiveness[186]. - The company has established a monitoring system for pollutant discharge, which is subject to real-time supervision by environmental regulatory authorities[185]. - The company reported a total COD discharge of 9.66 tons, well within the regulatory limit of 12 tons[184]. - The company has committed to timely rectification of any governance issues identified during self-inspections as part of its compliance with governance action requirements[179]. Research and Development - The company is focusing on technological innovation in the marine industry and health sector, leveraging national and provincial research platforms to enhance its competitive edge[60]. - The company reported a research and development investment of ¥24,643,337.32 in 2023, a decrease of 11.08% compared to ¥27,712,739.62 in 2022[75]. - The number of R&D personnel increased by 4.17% to 75 in 2023, compared to 72 in 2022[75]. - The company is developing HPV high-risk subtype detection technology to improve cervical cancer screening accuracy and efficiency, aiming for early detection and treatment opportunities[73]. - The company is enhancing its capabilities in in vitro diagnostics and precision medicine, with over 200 reagent products, of which nearly 150 have been certified and launched[113]. Governance and Management - The company has a robust governance structure, ensuring independence from major shareholders and maintaining effective operational control[138]. - The company is committed to maintaining a robust governance structure with the recent board changes aimed at enhancing operational efficiency[143]. - The company reported a significant leadership change with the resignation of multiple board members on August 18, 2023, due to term expiration[143]. - The company is undergoing a board re-election process, with new members being elected on August 18, 2023, including Huang Zhi Hua as acting chairman and vice president[144]. - The company has a strong leadership team with a mix of experienced executives[157]. Market Trends and Future Outlook - The company anticipates that by 2025, the contribution rate of technological progress in fisheries will reach 67%[36]. - The company aims to leverage its existing research, technology, and resources to accelerate the development of in vitro diagnostics and precision medicine, targeting both domestic and international markets[106]. - The company plans to establish a dual business model focusing on marine and health industries, enhancing profitability and international competitiveness[107]. - The health industry is projected to grow significantly due to factors like population aging, urbanization, and increased health awareness, driving demand for diverse health services[106]. - The company is expected to leverage its new board composition to drive future growth and innovation in its product offerings[144]. Challenges and Risks - The company faces risks from disease outbreaks in aquaculture, with potential annual economic losses exceeding hundreds of millions due to disease spread[118]. - The company will implement measures to monitor and control pollution in aquaculture areas to mitigate environmental risks[119]. - The company recognizes the risk of natural disasters affecting aquaculture operations and will leverage its advantageous location to minimize potential losses[119]. - The company acknowledges the lag in domestic market marketing efforts and aims to enhance its sales network to improve performance[124]. - The company is facing foreign exchange risks due to the appreciation of the RMB, which could lead to increased costs and reduced gross margins in its processing business[126].